Scope’s CRISPR Molecular Diagnostics CE Marked for Antifungal Resistance

October 6, 2026

Developed with AmplexDiagnostics, eazySNP brings scopeDx® into human diagnostics Scope Biosciences B.V., a Wageningen University spinoff life sciences...

CellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development

October 5, 2026

Collaboration combines CellCarta’s global clinical trial testing capabilities with Waters’ standardized flow cytometry platforms and expertise CellCar...

CellCarta and Imagene AI Expand Collaboration to Validate, Deploy and Scale AI-Powered Biomarker and...

October 1, 2026

The collaboration combines Imagene’s AI-powered assay development and biomarker prediction capabilities with CellCarta’s global companion diagnostics ...

Newsroom

Categories

Choose a Category

Subscribe to Email Updates

Sciensus to deliver a fully integrated home pathway for Tumour Treating Fields (TTFields) therapy

READ MORE

Inceptua Group and Cycle Pharmaceuticals partner for a Free Goods Programme for patients with Hereditary Tyrosinemia Type 1 (HT-1) and Alkaptonuria (AKU).

READ MORE

John Bell & Croyden celebrates key role of community pharmacists during COVID-19

READ MORE

Inceptua receives approval of marketing authorization transfer of Jetrea® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion

READ MORE

BioCity is the latest investor to back promising 'self care' venture

READ MORE

Browse more news

Recent releases

Scope’s CRISPR Molecular Diagnostics CE Marked for Antifungal Resistance

READ MORE

CellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development

READ MORE

CellCarta and Imagene AI Expand Collaboration to Validate, Deploy and Scale AI-Powered Biomarker and...

READ MORE

Useful information